Peroxisome proliferator-activated receptor γ agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation

Seoung Ju Park, Kyung Sun Lee, So Ri Kim, Kyung-Hoon Min, Yeong Hun Choe, Hee Moon, Han Jung Chae, Wan Hee Yoo, Yong Chul Lee

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Peroxisome proliferator-activated receptor γ(PPARγ) plays a critical role in the control of airway inflammation. Recently, IL-17 has been found to be implicated in many immune and inflammatory responses, including airway inflammation. However, no data are available concerning the effect of PPARγ on IL-17 production in airway inflammatory diseases. In this study, we used a mouse model of asthma to evaluate the effect of two PPARγ agonists, rosiglitazone or pioglitazone, on IL-17 expression in allergic airway disease. After OVA inhalation, mice developed the typical pathophysiological features of asthma, and the expression of IL-17 protein and mRNA in the lungs was increased. Administration of rosiglitazone or pioglitazone reduced the pathophysiological features of asthma and decreased the increased IL-17 protein and mRNA expression after OVA inhalation. In addition, the attenuating effect of PPARγ agonist on allergic airway inflammation and bronchial hyperresponsiveness is abrogated by coadministration of rIL-17. This study also showed that the inhibition of IL-17 activity with anti-IL-17 Ab remarkably reduced the increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, and the increased levels of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid and OVA-specific IgE in serum. In addition, we found that administration of rosiglitazone or pioglitazone decreased the increased NF-κB activity and that a NF-κB inhibitor, BAY 11-7085, substantially reduced the increased IL-17 protein levels in the lung tissues after OVA inhalation. These findings suggest that the therapeutic effect of PPARγ in asthma is partly mediated by regulation of IL-17 expression via NF-κB pathway.

Original languageEnglish
Pages (from-to)3259-3267
Number of pages9
JournalJournal of Immunology
Volume183
Issue number5
DOIs
Publication statusPublished - 2009 Sep 1
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
Interleukin-17
Down-Regulation
rosiglitazone
pioglitazone
Inflammation
Asthma
Inhalation
Lung
Messenger RNA
Proteins
Airway Management
Interleukin-13
Interleukin-5
Bronchoalveolar Lavage Fluid
Therapeutic Uses
Interleukin-4
Immunoglobulin E
Cell Count

ASJC Scopus subject areas

  • Immunology

Cite this

Peroxisome proliferator-activated receptor γ agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. / Park, Seoung Ju; Lee, Kyung Sun; Kim, So Ri; Min, Kyung-Hoon; Choe, Yeong Hun; Moon, Hee; Chae, Han Jung; Yoo, Wan Hee; Lee, Yong Chul.

In: Journal of Immunology, Vol. 183, No. 5, 01.09.2009, p. 3259-3267.

Research output: Contribution to journalArticle

Park, Seoung Ju ; Lee, Kyung Sun ; Kim, So Ri ; Min, Kyung-Hoon ; Choe, Yeong Hun ; Moon, Hee ; Chae, Han Jung ; Yoo, Wan Hee ; Lee, Yong Chul. / Peroxisome proliferator-activated receptor γ agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. In: Journal of Immunology. 2009 ; Vol. 183, No. 5. pp. 3259-3267.
@article{ca421d6d07084cccb591f9ff790a8c29,
title = "Peroxisome proliferator-activated receptor γ agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation",
abstract = "Peroxisome proliferator-activated receptor γ(PPARγ) plays a critical role in the control of airway inflammation. Recently, IL-17 has been found to be implicated in many immune and inflammatory responses, including airway inflammation. However, no data are available concerning the effect of PPARγ on IL-17 production in airway inflammatory diseases. In this study, we used a mouse model of asthma to evaluate the effect of two PPARγ agonists, rosiglitazone or pioglitazone, on IL-17 expression in allergic airway disease. After OVA inhalation, mice developed the typical pathophysiological features of asthma, and the expression of IL-17 protein and mRNA in the lungs was increased. Administration of rosiglitazone or pioglitazone reduced the pathophysiological features of asthma and decreased the increased IL-17 protein and mRNA expression after OVA inhalation. In addition, the attenuating effect of PPARγ agonist on allergic airway inflammation and bronchial hyperresponsiveness is abrogated by coadministration of rIL-17. This study also showed that the inhibition of IL-17 activity with anti-IL-17 Ab remarkably reduced the increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, and the increased levels of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid and OVA-specific IgE in serum. In addition, we found that administration of rosiglitazone or pioglitazone decreased the increased NF-κB activity and that a NF-κB inhibitor, BAY 11-7085, substantially reduced the increased IL-17 protein levels in the lung tissues after OVA inhalation. These findings suggest that the therapeutic effect of PPARγ in asthma is partly mediated by regulation of IL-17 expression via NF-κB pathway.",
author = "Park, {Seoung Ju} and Lee, {Kyung Sun} and Kim, {So Ri} and Kyung-Hoon Min and Choe, {Yeong Hun} and Hee Moon and Chae, {Han Jung} and Yoo, {Wan Hee} and Lee, {Yong Chul}",
year = "2009",
month = "9",
day = "1",
doi = "10.4049/jimmunol.0900231",
language = "English",
volume = "183",
pages = "3259--3267",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor γ agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation

AU - Park, Seoung Ju

AU - Lee, Kyung Sun

AU - Kim, So Ri

AU - Min, Kyung-Hoon

AU - Choe, Yeong Hun

AU - Moon, Hee

AU - Chae, Han Jung

AU - Yoo, Wan Hee

AU - Lee, Yong Chul

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Peroxisome proliferator-activated receptor γ(PPARγ) plays a critical role in the control of airway inflammation. Recently, IL-17 has been found to be implicated in many immune and inflammatory responses, including airway inflammation. However, no data are available concerning the effect of PPARγ on IL-17 production in airway inflammatory diseases. In this study, we used a mouse model of asthma to evaluate the effect of two PPARγ agonists, rosiglitazone or pioglitazone, on IL-17 expression in allergic airway disease. After OVA inhalation, mice developed the typical pathophysiological features of asthma, and the expression of IL-17 protein and mRNA in the lungs was increased. Administration of rosiglitazone or pioglitazone reduced the pathophysiological features of asthma and decreased the increased IL-17 protein and mRNA expression after OVA inhalation. In addition, the attenuating effect of PPARγ agonist on allergic airway inflammation and bronchial hyperresponsiveness is abrogated by coadministration of rIL-17. This study also showed that the inhibition of IL-17 activity with anti-IL-17 Ab remarkably reduced the increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, and the increased levels of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid and OVA-specific IgE in serum. In addition, we found that administration of rosiglitazone or pioglitazone decreased the increased NF-κB activity and that a NF-κB inhibitor, BAY 11-7085, substantially reduced the increased IL-17 protein levels in the lung tissues after OVA inhalation. These findings suggest that the therapeutic effect of PPARγ in asthma is partly mediated by regulation of IL-17 expression via NF-κB pathway.

AB - Peroxisome proliferator-activated receptor γ(PPARγ) plays a critical role in the control of airway inflammation. Recently, IL-17 has been found to be implicated in many immune and inflammatory responses, including airway inflammation. However, no data are available concerning the effect of PPARγ on IL-17 production in airway inflammatory diseases. In this study, we used a mouse model of asthma to evaluate the effect of two PPARγ agonists, rosiglitazone or pioglitazone, on IL-17 expression in allergic airway disease. After OVA inhalation, mice developed the typical pathophysiological features of asthma, and the expression of IL-17 protein and mRNA in the lungs was increased. Administration of rosiglitazone or pioglitazone reduced the pathophysiological features of asthma and decreased the increased IL-17 protein and mRNA expression after OVA inhalation. In addition, the attenuating effect of PPARγ agonist on allergic airway inflammation and bronchial hyperresponsiveness is abrogated by coadministration of rIL-17. This study also showed that the inhibition of IL-17 activity with anti-IL-17 Ab remarkably reduced the increased numbers of inflammatory cells of the airways, airway hyperresponsiveness, and the increased levels of IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid and OVA-specific IgE in serum. In addition, we found that administration of rosiglitazone or pioglitazone decreased the increased NF-κB activity and that a NF-κB inhibitor, BAY 11-7085, substantially reduced the increased IL-17 protein levels in the lung tissues after OVA inhalation. These findings suggest that the therapeutic effect of PPARγ in asthma is partly mediated by regulation of IL-17 expression via NF-κB pathway.

UR - http://www.scopus.com/inward/record.url?scp=70349249624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349249624&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.0900231

DO - 10.4049/jimmunol.0900231

M3 - Article

VL - 183

SP - 3259

EP - 3267

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -